logo
logo

Aprea Therapeutics raised $34.0M in a private placement financing led by Sphera Healthcare for clinical development of APR-1051, with participation from new and existing healthcare-focused institutional investors.

Mar 12, 2024•over 1 year ago

Amount Raised

$34 Million

DoylestownScience And EngineeringHealth CareBiotechnology

Investors

Stonepine Capital ManagementExome Asset ManagementDafna Capital ManagementNantahala CapitalSphera Healthcare

Description

Aprea Therapeutics, a clinical-stage biopharmaceutical company focused on precision oncology, announced a private placement financing of up to $34.0 million led by Sphera Healthcare, with participation from new and existing healthcare-focused institutional investors.

Company Information

Company

Aprea Therapeutics

Location

Doylestown, Pennsylvania, United States

About

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Doylestown, Pennsylvania, focused on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. The Company’s lead program is ATRN-119, a Phase 1-ready small molecule ATR inhibitor being developed for solid tumor indications. For more information, please visit the company website at www.aprea.com. The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People